TATA HEALTH (01255) announced that on September 12, 2025, the company received a letter from the Hong Kong Stock Exchange. The letter sets out additional guidance for the resumption of trading of the company's shares on the Hong Kong Stock Exchange, specifically requiring: conducting an independent internal control review and demonstrating that the company has established sufficient internal controls and procedures to comply with its obligations under the listing rules.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.